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Abstract
BACKGROUND: Detecting human papillomaviruses (HPVs) infection in cervical cells is an exceedingly important
part of the clinical management of cervical dysplasia. Current guidelines in women’s health outline the need for
both the Papanicolaou test as well as high-risk HPV testing. Testing for HPV is expensive, is time-consuming, and
requires experienced technicians. METHODS: Two sets of near-infrared Raman microspectroscopy experiments
were conducted using a Raman confocal microscope system. First, Raman spectra were acquired from four dif-
ferent cell culture lines, two positive for HPV (HeLa, SiHa), one negative for HPV, but malignant (C33A), and one
normal, HPV-negative line (NHEK). The three malignant lines were all derived from cervical cells. Second, Raman
spectra were acquired from deidentified patient samples that were previously tested for the presence of high-risk
HPV. RESULTS: The spectra from the cell culture lines and the patient samples contained many statistically signif-
icant differences. Using sparse multinomial logistic regression to classify the data led to classification accuracies
of 89% to 97% for the cell culture samples and 98.5% for the patient samples. CONCLUSIONS: Raman micro-
spectroscopy can be used to detect HPV and differentiate among specific HPV strains. This technique may provide
health providers with a new method for quickly testing cell samples for the presence of HPV.
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Introduction
Persistent infections with sexually transmitted human papilloma-
viruses (HPVs) are correlated with essentially all cases of cervical
cancer [1]. Of more than 150 HPV strains, a limited number of high-
risk strains (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 69)
have been found to cause cervical cancer [2,3]. Of these, two high-risk
HPV strains, 16 and 18, together cause 70% of cervical cancer cases
worldwide. These high-risk strains predominantly infect skin and
mucosal membranes to promote epithelial proliferation, resulting in
uninhibited proliferation and malignant transformations. Three
oncogenes, E5, E6, and E7, are found in high-risk HPV strains and
cause cell damage and abnormal cell proliferation by cooperatively
interfering with the functions of cellular tumor suppressor proteins,
specifically p53 and pRb [4]. Because HPV infects basal layer cells
and only replicates in fully differentiated cells, it can usually remain
undetected by the immune system, avoiding a humoral or cell-mediated
immune response for years [5].
The Papanicolaou (Pap) test, where cells are scraped from the cer-
vix and examined for atypical cytologic features under a microscope,
was introduced in the early 1920s. Since then, clinical management
of cervical dysplasia has been achieved by administering regular Pap
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tests. However, Pap tests alone do not provide a complete picture of
the possible malignant changes that occur in the cervix due to HPV
infection. Since 2009, the American Society of Colposcopy and
Cervical Pathology has recommended including HPV testing for
the clinical management of cervical dysplasia in women [6]. There-
fore, in the past few years, testing for all high-risk HPV strains or
only strains 16 and 18 has been incorporated into routine cervical
cancer screening in women older than 30 years, leading to more
accurate results and a reduction in the overall number of Pap tests
as women who have both a negative Pap result and a negative
HPV-DNA test result are only retested every 2 to 3 years.
Current testing methods rely on obtaining a cellular sample, fixing
the cells on a slide, and then transporting the slide to a pathology
laboratory that runs the HPV test. After 7 to 12 days, the test results,
whether the cell sample is positive or negative for a high-risk strain of
HPV, are reported. No tests currently used for routine screening
report the specific high-risk strain. The HPV tests developed by
Qiagen, Roche, Gen-Probe, and Hologic are the most commonly
used [7,8]. Cervista only tests for HPV types 16 and 18 and is approved
for use in conjunction with Pap tests in women older than 30 years [9].
In cases where the Pap smear shows malignant cells and the sample is
positive for high-risk HPV, the patient then needs to return for a fol-
low-up appointment for either another Pap test or a colposcopy-guided
biopsy. A diagnostic tool that can rapidly identify specific high-risk
HPV strains in vivo or ex vivo would help medical providers determine
appropriate follow-up treatment to diagnose cervical dysplasia and pre-
vent its progression.
Two HPV vaccines, Gardasil and Cervarix, prevent infection from
high-risk HPV strains 16 and 18 [9,10]. These vaccines are available
to women ages 9 to 26 and some men only on a voluntary basis.
However, these vaccines may not protect against the other high-risk
HPV types, which are common in countries other than the United
States [11,12]. A tool for identifying cervical samples that are positive
for high-risk strains of HPV remains necessary even with the increas-
ing use of HPV vaccines.
Optical techniques, such as drug-mediated fluorescence [13],
autofluorescence [14], Fourier transform infrared (FTIR) spectros-
copy [15], and Raman spectroscopy (RS) [16–18] have been used
to detect cervical dysplasia. As the clinical management of cervical
cancer has shifted more recently, some of these techniques have been
extended to the detection of infection with HPV. Such methods can
be used noninvasively, directly on the cervix either to detect dysplasia
or to detect the presence of HPV in small volumes of ex vivo samples.
The results from these studies have ranged from detecting the differ-
ence between HPV-positive and -negative samples with sensitivities
and specificities ranging from 90% to 94% [13,15] and from 92% to
96% [13,15,17], respectively, to understanding the important spectral
signatures that are associated with different types of HPV infection
without a diagnostic application. These optical techniques do have their
drawbacks, however, because fluorescence signal increases with HPV
infection, regardless of strain, and FTIR is significantly hindered by
water content, a significant hurdle for potential in vivo applications.
In this study, we use a confocal Raman microspectroscopy system
to study the biochemical characteristics of various HPV strains and
malignant cervical cells. RS is based on the inelastic scatter effect,
where incident light is scattered from a molecular or cellular sample.
This scattered light exhibits an energy shift that reports the energy of
specific molecular vibrations within the sample, effectively providing a
detailed biochemical composition or fingerprint. A Raman spectrum,
therefore, plots the energy shift away from the incident wavelength,
usually measured in relative wavenumbers, versus scattering intensity.
This optical technique can objectively characterize samples from mul-
tiple tissues based solely on their biochemical constituents, without
relying on specific chemical markers or exogenous agents [19–21].
Previously, we have acquired Raman spectra from bulk cervical tis-
sue in vivo using a fiber-optic tool to detect and differentiate types of
cervical dysplasia within a diverse patient population [18,22]. Re-
cently, we have found that accounting for patient variables, such as
menopausal status or previous pregnancies, can lead to an increase
in disease classification accuracy [16,22]. Infection with HPV is also
an important variable that has yet to be included in these analyses
because not every patient is tested for HPV, and the most widely used
testing standards do not differentiate between various HPV strains.
The goal of this study was to evaluate the ability of RS to detect
the presence of HPV and the differences between specific HPV
strains. Therefore, in this study, two sets of experiments were con-
ducted to determine whether RS is sensitive to HPV infection. First,
Raman spectra were acquired using a Raman confocal microscope
from four different cell lines: HPV-16–positive SiHa cells, HPV-
18–positive HeLa cells, HPV-negative but malignant C33A cells,
and benign NHEK cells. Next, Raman spectra were obtained from
HPV-positive and -negative patient samples. Logistic regression algo-
rithms were then used to classify spectra into either specific strain
categories for the cell culture studies or HPV-positive or -negative
for the patient samples. Other research groups have performed sim-
ilar tests acquiring Raman spectra from HPV-expressing cell lines
[23,24]. However, these studies omitted either a positive or a nega-
tive control. Also, many of these studies only reported on the onco-
genic component of the virus (i.e., E7), instead of a complete HPV
infection. Furthermore, to our knowledge, no study has incorporated
Raman spectra acquired from HPV-positive and HPV-negative patient
samples into their analysis of the sensitivity of RS toward HPV.
Materials and Methods
Two sets of experiments were conducted to evaluate the ability of RS
to differentiate between HPV strains in cell culture lines and the
presence of high-risk HPV strains in patient samples.
Cell Culture and Sample Preparation
In the first set of experiments, four cell types with different HPV
strains or no HPV infection (Table 1) were used. First, the two
HPV-expressing cells, SiHa and HeLa (ATCC, Manassas, VA), were
grown in RPMI with L-glutamate medium with 10% fetal bovine
serum and antibiotics (Gibco, Carlsbad, CA). SiHa cells express
Table 1. Description of Cell Culture and Patient Samples Used in This Study.
HPV-Positive Transformed
(Malignant)
Cell culture sample
SiHa cell culture Yes – HPV-16, 1-2 copies Yes
HeLa cell culture Yes – HPV-18, 10-50 copies Yes
C33A cell culture No Yes
NHEK cell culture No No
Patient samples
HPV-positive (nsamples = 25) Yes — one or more high-risk strains Potentially
HPV-negative (nsamples = 25) Negative for high-risk strains No
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HPV-16 and HeLa cells express HPV-18, two high-risk strains. A
C33A cell line (ATCC), transformed but HPV negative, was grown
in Dulbecco modified Eagle medium with 10% fetal bovine serum
and antibiotics. NHEK cells (a human keratinocyte cell line) were
grown in EpiLife Media (Gibco) and antibiotics.
Once the cells reached approximately 90% confluence in a T-75
flask (on average, 18.2 × 106 cells), the cells were washed with PBS
and trypsinized (medium was used to stop the trypsinization process).
The cell mixture was then centrifuged at 300g for 5 minutes. After the
supernatant was removed, 10 ml of PBS was added, and the mixture
was centrifuged. This process was repeated three times. Next, 10 ml
of sterile water was added, and the cell-water mixture was centrifuged
at 300g for 5 to 7 minutes, also repeated three times. Finally, the
supernatant was removed, and the cellular pellets were transferred
onto CaF2 slides (Crystran, Dorset, United Kingdom). The slides
were allowed to air dry in a sterile environment overnight. Raman
spectra were acquired the next day. This protocol was developed to
minimize the effects of the different types of medium used to grow
each cell type, while maximizing cell growth.
Patient Samples and Preparation
After approval from the Vanderbilt University Institutional Review
Board was obtained, HPV-positive (nsamples = 25) and -negative
(nsamples = 25) deidentified patient samples were obtained from
the Molecular Infectious Diseases Laboratory at Vanderbilt University
(Table 1). The samples were initially acquired for standard HPV test-
ing, which includes cells from the cervix also used in liquid-based
Pap tests. Vanderbilt University uses the digene HC2 HPV DNA test
developed by Qiagen (Valencia, CA). After 8 weeks, when samples are
typically discarded, we were able to acquire 50 samples. Each sample
contained 20 μl, with an average of 9 × 104 cells (fewer than the cell
culture samples). Each cell sample was centrifuged at 300g for 5 min-
utes. After the supernatant was removed, 10 ml of sterile water
was added, and the mixture was centrifuged again. This process was
repeated three times. Finally, the supernatant was removed, and the
cellular pellets were transferred onto CaF2 slides (Crystran). The slides
were allowed to air dry in a sterile environment overnight. Raman
spectra were acquired the next day.
Raman Microspectroscopy Measurements
Confocal Raman microspectroscopy provides a platform for acquir-
ing detailed Raman spectra from small volumes. The RenishawInVia
Raman microscope (Gloucestershire, United Kingdom; Figure 1) con-
sists of a temperature-stabilized diode near-infrared laser with a maxi-
mum power of 120 mW (Innovative Photonics, Monmouth Junction,
NJ) that operates at 785 nm and delivers∼30 mW to the sample. Light
was guided through a collimator onto a series of mirrors that focused
the light through an open field 50× microscope lens. Dried cell pellets
were illuminated with the laser beam using a microscope objective lens
(Leica N Plan 50×/0.75, Wetzlar, Germany). Scattered light from a 2-
to 3-μm illuminated spot was collected with the same objective lens via
a 180-degree backscatter sampling geometry. Rayleigh scattering inten-
sity was reduced by the use of angle-tuned dielectric edge filters allow-
ing OD6 rejection of the laser line. The inelastic (Raman) scattered
light was then focused through a slit (100-μm width) and dispersed
by a diffraction grating (600 grooves per millimeter) onto an air-cooled,
deep-depleted CCD detector (576 × 384 pixels; each pixel is 22 ×
22 μm, −70°C). Raman spectra were then processed as described in the
next paragraph. This system yields a resolution of ∼6 cm−1, compared
with the resolution of ∼8 cm−1 found with portable probe-based systems
used by this research group. For the cell culture samples, spectra were
acquired with an exposure time of 30 seconds. For the patient samples,
Figure 1. Schematic of Renishaw confocal Raman system. (© Renishaw)
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spectra were acquired with an exposure time of 45 to 60 seconds. Three
accumulations were acquired at each acquisition point, with a binning of 3.
The spectra were processed for fluorescence subtraction and noise
smoothing using the modified polynomial fit and Savitzky-Golay
methods, described previously [25]. After data processing, each spec-
trum was normalized to its mean spectral intensity across all Raman
bands to account for intensity variability.
Analysis and Classification of Raman Spectra
A Student’s t test (unpaired two-sample, equal variance) was first
conducted to find regions of significant differences among the four
cell culture samples and between the two patient samples. Next, clas-
sification algorithms were used to tease out subtle differences among
spectra acquired from different samples. For this study, a logistic reg-
ression method called sparse multinomial logistic regression (SMLR)
was used [26]. In brief, SMLR is a Bayesian machine learning frame-
work that computes the posterior probability of a spectrum belonging
to each pathology class based on a labeled training set. For these anal-
yses, a composite spectrum averaging Raman measurements from
each cell culture or patient sample was used. A range of input param-
eters to SMLR was tested. The settings that provided the most
accurate classification while also maximizing sparsity among the
samples were a Laplacian prior, a direct kernel, a lambda value of
0.01, and no additional bias term. After every analysis, a confusion
matrix that displays how each spectrum classified was produced,
which can be presented as either the total number of spectra or a
percentage. Also, each SMLR analysis provides a training algorithm
that can be used for validation.
For the cell culture samples, three sets of SMLR analyses were
used. First, HPV-positive samples (HeLa, SiHa) were compared with
HPV-negative samples (C33A, NHEK). Next, malignant samples
(HeLa, SiHa, C33A) were compared with the benign sample
(NHEK). Finally, SMLR was used to classify each cell line. For
the patient samples, HPV-positive and HPV-negative samples were
Figure 2. SpectraofHeLa,SiHa,C33A, andNHEKcell culture samples.
Figure 3. Specific wavenumbers and ratios of wavenumbers from spectra of cell culture samples with ±standard error. *P < .01 when
compared to HeLa cells.
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classified using SMLR. The algorithm developed from the patient
samples was then applied to classify the cell samples.
Results
The goal of this study was to determine whether the differences be-
tween HPV-positive and -negative samples, malignant and benign
samples, and specific HPV strains from cell culture and patient sam-
ples can be detected using RS (Table 1). Approximately 30 Raman
spectra were obtained from 15 independent samples, consisting of at
least 1 × 104 cells per sample. The power of the cell culture experi-
ments is greater than 90% (two-sided statistical test, α = 0.05) with
an effect size of 1; the power of the human sample study is greater
than 80% under the same criteria. Figure 2 displays the Raman spec-
tra acquired with the Raman microscopy system from four cell cul-
ture samples: HeLa, SiHa, C33A, and NHEK. Spectra acquired from
the fixed HeLa cells seem to be the most different visually across the
range of the spectrum, specifically around 990, 1080 to 1160, around
1400, and around 1670 cm−1. These areas have been shown in previ-
ous work to correspond to C–C stretching in lipids and proteins,
DNA content, and CH2 deformation [27].
In Figure 3, peaks and peak ratios of the spectra in Figure 2 are
displayed to provide an in-depth view of the changes that occur in
the spectra from different cell lines. Figure 3 (A and B) demonstrates
that concentrations of molecules vary depending on cell type, HPV
strain, and the number of HPV copies. Specifically, wavenumber
1260 has been tentatively assigned to the deformation of CH3 bonds
and amide III [28]. Wavenumber 1400 cm−1 has been shown to
correspond to DNA and RNA components, such as uracil and ade-
nine [27]. Looking at the changes among ratios of wavenumbers is
another method commonly used to interpret Raman spectra. Fig-
ure 3C shows the ratio of 1650 to 1440 cm−1, which is one way of
describing the intensity of the CH2 bending and the intensity of the
C=C stretch [29]. In these samples, this ratio has a negative linear
dependence on HPV infection and malignancy, leading to a decrease
in the ratio. In Figure 3D, the ratio of 1260 cm−1 to 1340 cm−1 or the
ratio of Amide III to amino acids is displayed [30]. In this case, as the
number of copies of HPV increases in each sample (1-2 in SiHa cells,
10-50 in HeLa cells), this ratio increases, resulting in a linear correla-
tion between HPV infection and this ratio [31]. A Student’s t test was
also performed to compare the differences in the peak intensities to
HeLa cells. P < .01 was defined as significant.
The first step of this analysis to determine the clinical significance
of this technique was to use SMLR to classify the cell culture samples
as HPV-positive or -negative (Table 2). Table 2 shows that the pres-
ence of HPV is correctly identified using RS with a classification
accuracy of 97%. Next, the analyses classified the spectra as malig-
nant or benign (Table 3). Combining the malignant cell lines for
comparison to the NHEK benign cell line resulted in a lower classi-
fication accuracy of 92%, with 10% of the Raman spectra obtained
from malignant cells classifying as normal. Finally, SMLR was used
to classify the spectra from the four different cell culture types with
an accuracy of 89% (Table 4). The HeLa samples had the highest
classification accuracy (98%), whereas the HPV-negative, malignant
cells (C33A) had the lowest (84%) with 8% of its spectra classifying
as normal.
Figure 4 shows the spectra acquired from patient samples that
were tested for the presence of high-risk strands for HPV. Spectra from
these two samples vary significantly across the 600- to 1800-cm−1
range, in many of the same regions listed above, but also in areas
corresponding to both Amide III and Amide I (1200-1300 and
1660 cm−1, respectively) [30]. P values less than .001, resulting from
a Student’s t test, are also shown on this graph, demonstrating that
many regions of the spectra obtained from HPV-positive and -negative
samples are significantly different.
The classification algorithm SMLR was also used to classify patient
samples as HPV positive or negative, and the results were compared
with the HPV test result. These spectra from patient samples were
classified with an accuracy of 98.5% (Table 5). The training algo-
rithm that resulted from using SMLR on the patient samples was
then applied to both the malignant and the benign classifications
(data not shown) and the classification of the four different cell cul-
ture lines. When the classification algorithm derived from the patient
data was used to classify malignant and normal samples, the classifi-
cation accuracy increased from 92% to 93%. For classifying the four
cell culture lines, using the patient sample algorithm instead of the
cell culture algorithm resulted in an increase in classification accuracy
from 89% to 93% (Table 6). The spectra acquired from HeLa and
SiHa cells maintained their previous classification accuracies, but the
C33A and NHEK spectra increased their classification accuracies by
5% and 1%, respectively.
Discussion
The results of this study demonstrate that RS is able to differentiate
between various cell culture samples as well as patient samples, based
on the presence of HPV alone and the specific HPV strain. These
results may positively contribute to screening for cervical disease
by determining if cervical samples are positive for high-risk strains
of HPV.
In Figure 2, there are certain regions that are more variable,
including those corresponding to C=C stretching in lipids and
Table 2. Classification Table for HPV-Positive Versus HPV-Negative Cell Culture Samples.
Classification Accuracy: 97% Raman Classification, Output
of SMLR
HPV-Positive
(HeLa, SiHa)
HPV-Negative
(C33A, NHEK)
Cell culture
sample type
HPV-positive
(HeLa, SiHa, nspectra = 1365)
98% (1338) 2% (27)
HPV-negative
(C33A, NHEK, nspectra = 1390)
4% (56) 96% (1334)
The number of Raman spectra from each samples type is in parentheses. Bolded numbers along
the diagonal represent the spectra that classified correctly.
Table 3. Classification Table for Malignant and Normal Cell Culture Samples.
Classification Accuracy: 92% Raman Classification, Output
of SMLR
Malignant
(HeLa, SiHa, C33A)
Normal
(NHEK)
Cell culture
sample type
Malignant
(HeLa, SiHa, C33A, nspectra = 2075)
90% (1868) 10% (207)
Normal
(NHEK, nspectra = 680)
6% (41) 94% (639)
The number of Raman spectra from each samples type is in parentheses. Bolded numbers along
the diagonal represent the spectra that classified correctly.
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proteins, DNA content, and CH2 deformation. Also, the SiHa, C33A,
and NHEK spectra seem to resemble each other more than the HeLa
spectra. HeLa cells have the most copies of HPV, which may result
in a more malignant cell line that has a higher concentration of
DNA than the other cells types. The deformation of both proteins
and lipids, found within cells and the phospholipid membrane, is
observed in the Raman spectra acquired from more advanced malig-
nant cell lines and those with a higher number of copies of high-
risk strains of HPV [31]. These changes may be associated with
the increased disorganization caused by HPV infection and more
advanced malignancy.
When smaller regions of the spectra are considered, differences can
be observed among the cell culture samples. These differences may
be related to HPV infection, the number of copies of HPV, and the
transformation of the cell line. The two ratios that have been graphed
(Figure 3, C and D) demonstrate some of the biochemical changes
that occur as cells with and without HPV infection advance malig-
nantly. The 1650-to-1440-cm−1 ratio demonstrates that, as the cell
develops increasingly malignant characteristics and as the number of
HPV copies increases, the ratio of CH3 bending to C=C stretching
decreases. This result suggests an increase in disorganization occur-
ring at a cellular level. The 1260-to-1340-cm−1 ratio corresponds
to Amide III and the amount of amino acids (Figure 3D), suggesting
that there are slight increases in the amount of protein as the cells
become malignant and infected with HPV. It is also interesting to
note that, although the C33A cell line is a transformed, malignant
cell line, it mostly resembles the spectra obtained from the normal
NHEK cell line. This result suggests that infection with HPV is
the more pertinent feature affecting Raman spectra.
The spectra obtained from patient samples seem to be dramatically
different based only on infection with high-risk strains of HPV (Fig-
ure 4), verifying the hypothesis that RS is sensitive to HPV infection.
The differences between the spectra are seen in multiple regions, such
as those corresponding to lipid, amino acid, and DNA content, as well
as CH stretching and bending regions that have been assigned to
proteins such as albumin and collagen [31]. Many of these differences
correlate with changes that occur in patient samples that are positive for
at least one high-risk HPV strain. Specifically, an increased DNA
content and density is found with an increased amount of phosphate
and an increasing amount of disorganization, seen throughout the
spectra as the deformation and breakdown of CHx bonds [31]. Further-
more, the concentration of lipids (tentatively assigned to 1450 cm−1)
seems to decrease as the number of copies of HPV increases.
Developing SMLR algorithms based on the spectra from the cell
culture samples led to classification accuracy rates from 89% to 97%.
Spectra of HPV-positive and HPV-negative cells were classified with
an accuracy of 97% (Table 2). As discussed, HPV infection leads to
modifications within the cellular environment by circumventing nor-
mal cell growth pathways, specifically by increasing DNA synthesis.
This phenomenon can be observed in the spectra because the density
or organization of DNA is lower in HPV-positive cells because the
DNA is transcriptionally active, as opposed to densely packed and
quiescent [32]. Next, SMLR differentiated between three malignant
cell lines and one benign cell line with a classification accuracy of
92% (Table 3). This result is lower than the result from discriminat-
ing the HPV-positive and -negative cell lines, most likely due to the
addition of the HPV-negative cell line (C33A) into the malignant
category. C33A is a transformed, malignant epithelial cervical cell
line; however, its spectra is closer to the spectra obtained from
NHEK cells than the HPV-positive cell lines. Therefore, it is not
surprising that 10% of the spectra obtained from C33A samples were
misclassified. Clinically, a patient having malignant cervical cells
without the presence of HPV is a very rare occurrence, accounting
for approximately 0.01% of all cases of cervical dysplasia [33].
Table 4. Classification Table for All Four Cell Culture Samples (HeLa, SiHa, C33A, and NHEK).
Classification Accuracy: 89% Raman Classification, Output of SMLR
HeLa SiHa C33A NHEK
Cell culture
sample type
HeLa (nspectra = 675) 98% (661) 1% (7) 1% (7) 0% (0)
SiHa (nspectra = 690) 2% (14) 96% (662) 1% (7) 1% (7)
C33A (nspectra = 710) 3% (21) 5% (36) 84% (596) 8% (57)
NHEK (nspectra = 680) 1% (7) 2% (14) 9% (61) 88% (598)
The number of Raman spectra from each samples type is in parentheses. Bolded numbers along
the diagonal represent the spectra that classified correctly.
Figure 4. Spectra of HPV-positive versus HPV-negative patient
samples. Black line represents regions of significant difference
(P < .001) when the two samples are compared.
Table 5. Classification Table for HPV-Positive and -Negative Patient Samples.
Classification Accuracy: 98.5% Raman Classification, Output
of SMLR
HPV-Positive HPV-Negative
Pathologic diagnosis HPV-positive (nspectra = 840) 98% (823) 2% (17)
HPV-negative (nspectra = 875) 1% (9) 99% (866)
The number of Raman spectra from each samples type is in parentheses. Bolded numbers along
the diagonal represent the spectra that classified correctly.
Table 6. Classification Table for Cell Culture Samples (HeLa, SiHa, C33A, and NHEK) Using
the Algorithm Derived from Patient Samples (used in Table 5).
Classification Accuracy: 93% Raman Classification, Output of SMLR
HeLa SiHa C33A NHEK
Cell culture
sample type
HeLa (nspectra = 675) 98% (661) 1% (7) 1% (7) 0% (0)
SiHa (nspectra = 690) 2% (14) 96% (662) 1% (7) 1% (7)
C33A (nspectra = 710) 2% (14) 4% (28) 89% (632) 5% (36)
NHEK (nspectra = 680) 1% (7) 2% (14) 8% (54) 89% (605)
The number of Raman spectra from each samples type is in parentheses. Bolded numbers along
the diagonal represent the spectra that classified correctly.
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Management of such patients, therefore, would depend solely on the
results of their Pap tests.
The lowest classification accuracy from the cell culture study was
achieved when all four cell types were classified independently, result-
ing in an accuracy of 89% (Table 4). The normal NHEK cells clas-
sified correctly only 89% of the time, perhaps because of the
similarities between the NHEK and C33A spectra from the lack of
HPV infection, as discussed above. It is also important to note that
SMLR was able to correctly classify greater than 95% of the spectra
obtained from HeLa and SiHa cells. The difference between these
cells is likely due to the type of HPV (18 vs 16) infection as well as
the number of copies of HPV in each line (estimated 10-50 copies of
HPV 18 in HeLa cells vs 1-2 copies of HPV 16 in SiHa cells).
HPV-positive and -negative patient samples were also classified
using SMLR with an accuracy of 98.5% (Table 5). This result corre-
sponds with the differences observed between the two spectra, quan-
tified by the low P values across the spectral range. Similar to the cell
culture studies, classifying patient samples based on the presence of
HPV, as opposed to HPV type or copy number, leads to extremely
promising results. The algorithm generated by SMLR based on the pa-
tient data set was then applied to previous data obtained from the cell
culture samples to determine if the differences between the patient sam-
ples were more representative of the differences between HPV-positive
and -negative cell lines. This algorithm was applied to the sets of the
malignant and benign samples (data not shown) and the four different
cell lines (Table 6). Both sets of data were classified with a higher accu-
racy when the patient-data algorithm was used. More specifically, using
the patient-data algorithm led to an increase in the classification of both
the C33A and NHEK cells by decreasing their incorrect assignments to
each other (i.e., when C33A spectra classified as NHEK spectra), imply-
ing that the algorithm developed from the patient data contains more
accurate information about HPV-negative cells. It is also interesting to
note that only a few cells in a patient sample needed to be infected with
high-risk HPV strands to be considered HPV positive. On the other
hand, it is assumed that all the cells from HPV-negative samples were
HPV negative. Future work will determine the detection limit of our
RS system for detecting patient samples that are positive and negative
for HPV in comparison to current HPV tests.
A few studies by other groups have shown that the presence of the
biomarker protein p16INK4A has a great influence on cells infected
with HPV [34–36]. p16INK4A is a minichromosome maintenance
protein found normally in cervical cells [33]. This protein is one
of many that regulate the level of active cyclin D/CDK, part of
the feedback loop involved in maintaining levels of minichromosome
maintenance proteins, proliferating cell nuclear antigens, and cyclin
E. p16INK4A is one of the biomarkers that correspond to elevated E7
expression and, therefore, to high-risk HPV infection. Overexpres-
sion of p16INK4A has been detected in all grades of cervical lesions
[34,36]. Results from FTIR and confocal fluorescence microscopy
studies on p16INK4A has shown that overexpression of p16INK4A and
HPV infection result in an increase in nucleic acid levels, a decrease
in lipid levels, and a moderate to low change in protein levels [35].
The Raman spectra correspond to these results, showing a biochemical
increase in nucleic acid levels and a decrease in lipid levels (Figure 3).
Current studies are focused on correlating the presence of biomarkers
with HPV-positive or -negative status within the Raman data.
Recent studies have shown that combining HPV testing with the
Pap test is more effective than the Pap test alone at detecting clini-
cally relevant high-grade dysplasia early, and results led to increased
prevention against more aggressive forms of cervical dysplasia in
women older than 30 years [37]. In fact, dual screening detected
25% more potentially cancerous lesions than a Pap test alone and
resulted in fewer cancer cases 5 years later compared with patients
who were only screened with a Pap test. Whereas previous work
shows that RS is capable of detecting dysplastic areas of the cervix
[16–18], this research demonstrates that RS is capable of detecting
HPV-infected cells as well. Therefore, RS could potentially be used
as an alternative method to Pap tests and HPV screening to detect
abnormal areas of the cervix and the presence of HPV in vivo and in
real time. Although in vivo samples were not used in this study,
because HPV testing is now recommended for women older than
30 years, in vivo Raman measurements can be taken concurrently
with HPV DNA testing. This work is being pursued currently.
Results from this article demonstrate that RS is sensitive to changes
occurring in cells due to HPV infection, HPV type, and the number
of copies of HPV. This technique can be combined with current
methods used to screen for cervical dysplasia to provide a tool that
can detect the presence of HPV immediately without the need for
extensive sample preparation, quickly leading to accurate results.
Current studies within our laboratory are focused on using the same
technique to study the differences between low-risk and high-risk
HPV strains. HPV testing is being introduced in conjunction with
our ongoing in vivo Raman study for cervical dysplasia detection to
obtain in vivo measurements with the presence of HPV.
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